Prognostic value of epidermal growth factor receptor in patients with gastric cancer: A meta-analysis

Gene

Volumn 529, Issue 1, 2013, Pages 69-72

  Hong, Liu ^a   Han, Yu ^a   Yang, Jianjun ^a   Zhang, Hongwei ^a   Jin, Yan ^a   Brain, Lubi ^b   Li, Mengbin ^a   Zhao, Qingchuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Epidermal growth factor receptor; Gastric cancer; Prognosis; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COCHRANE LIBRARY; EMBASE; GENE EXPRESSION; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; SCIENCE DIRECT DATABASE; STOMACH CANCER; SYSTEMATIC REVIEW;

CIS; CONFIDENCE INTERVALS; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; GASTRIC CANCER; HAZARD RATIOS; HRS; IHC; IMMUNOHISTOCHEMISTRY; MOOSE; OBSERVATIONAL STUDIES IN EPIDEMIOLOGY GROUP; PROGNOSIS; SURVIVAL;

CONFIDENCE INTERVALS; HUMANS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS;

EID: 84883556549     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.07.106     Document Type: Article

References (26)

1. Atmaca A., et al. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer 2012, 12:524. (2012 Nov 15). 10.1186/1471-2407-12-524.
2. Blum M.A., Takashi T., Suzuki A., Ajani J.A. Management of localized gastric cancer. J. Surg. Oncol. 2013, 107:265-270.
3. Chan J.A., et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann. Oncol. 2011, 22:1367-1373.
4. Guggenheim D.E., Shah M.A. Gastric cancer epidemiology and risk factors. J. Surg. Oncol. 2013, 107:230-236.
5. Han S.W., et al. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci. 2010, 101:793-799.
6. Hong L., et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert. Opin. Biol. Ther. 2010, 10:1693-1701.
7. Hong L., Yang J., Han Y., Lu Q., Cao J., Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene 2012, 507:135-138.
8. Hong L., Han Y., Zhang H., Zhao Q., Yang J., Ahuja N. High expression of epidermal growth factor receptor might predict poor survival in patients with colon cancer: a meta-analysis. Genet. Test. Mol. Biomark. 2013, 17:348-351.
9. Hong L., Zhang H., Zhao Q., Han Y., Yang J., Brain L. Relation of excess body weight and survival in patients with esophageal adenocarcinoma: a meta-analysis. Dis. Esophagus 2013, (2013 Jan 14, [Epub ahead of print] PubMed PMID: 23317016). 10.1111/dote.12016.
10. Inokuchi M., et al. Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer. Exp. Ther. Med. 2011, 2:251-256.
11. Iqbal S., et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann. Oncol. 2011, 22:2610-2615.
12. Jácome A.A., et al. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. Gastric Cancer 2013, (2013 Feb 28. [Epub ahead of print] PubMed PMID: 23455716).
13. Kim J.W., et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 2009, 272:296-306.
14. Kim J.S., et al. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br. J. Cancer 2009, 100:732-738.
15. Liao G., Wang Z., Zhao L., Zhang N., Dong P. Inhibitory effects of cytoplasmic-domain substituted epidermal growth factor receptor on growth, invasion and angiogenesis in human gastric cancer cells. Mol. Med. Rep. 2010, 3:287-294.
16. Liao G., Wang Z., Zhang N., Dong P. Dominant negative epidermal growth factor receptor inhibits growth of human gastric cancer cells by inducing cell cycle arrest and apoptosis. Cancer Biother. Radiopharm. 2013, 28(6):450-458.
17. Lieto E., et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann. Surg. Oncol. 2008, 15:69-79.
18. Luo H.Y., et al. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol. Rep. 2010, 23:1735-1745.
19. Matsubara J., et al. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008, 74:76-83.
20. Matsubara J., et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin. Cancer Res. 2008, 14:3022-3029.
21. Seshacharyulu P., Ponnusamy M.P., Haridas D., Jain M., Ganti A.K., Batra S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16:15-31.
22. Sylvie L., Susanne B., Katja O. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Recent Results Cancer Res. 2012, 196:269-289.
23. Terashima M., et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin. Cancer Res. 2012, 18:5992-6000.
24. Troiani T., et al. Targeting EGFR in pancreatic cancer treatment. Curr. Drug Targets 2012, 13:802-810.
25. Waddell T., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013, 14:481-489.
26. Wainberg Z.A., et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 2010, 16:1509-1519.